A Study of the Safety and Efficacy of Multiple Doses of ABT-089 in Subjects With Alzheimer's Disease

Stopped early · Phase 2

Conditions studied: Alzheimer's Disease

In brief

The purpose of this study is to compare the safety and efficacy of 2 mg, 4 mg, and 20 mg of ABT-089 BID to placebo in adults with Alzheimer's disease.

Key facts

Study ID

NCT00069849

Run by

Abbott

People needed

64

Starts

2003-07-01

Last updated by the study team

2006-09-04

Who can join

Age: 50 and older, up to 85. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Current diagnosis of probable Alzheimer's disease.
• ADAS-cog score of at least 12 and MMSE score of 10 to 26.
• Non-smoker
• Must have legally authorized representative and a reliable caregiver. The caregiver and legally authorized representative may be the same person.
• Fluent in English.

You may not qualify if…

• Use of cholinesterase inhibitors or any other drugs to treat Alzheimer's disease in the last 6 weeks.
• Has clinically significant or uncontrolled medical condition other than Alzheimer's disease.
• Nursing home resident.

Where it is running

• Study site — Fresno, California, United States
• Study site — San Diego, California, United States
• Study site — Orlando, Florida, United States
• Study site — West Palm Beach, Florida, United States
• Study site — Florence, Kentucky, United States
• Study site — Portland, Oregon, United States
• Study site — Salt Lake City, Utah, United States
• Study site — Bennington, Vermont, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.